Regeneron/Sanofi's Dupixent Approval Signals Major Treatment ...
17 hours ago · Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA’s (NASDAQ: SNY) Dupixent recently gained FDA approval for COPD, marking its sixth U.S. indication since …
Dupixent approved in the US as the first-ever biologic medicine …
Sep 27, 2024 · Dupixent has a proven track record as a first-in-class medicine, providing benefit to the many patients suffering from type 2 inflammatory related diseases such as asthma and …
Sanofi’s Dupixent Gains EU Approval for Pediatric Eosinophilic ...
Nov 7, 2024 · Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with eosinophilic esophagitis, expanding its market potential and offering new hope …
EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients
Nov 7, 2024 · SNY. REGN. The European Medicines Agency (EMA) approved Sanofi/Regeneron’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as …
Press Release: Dupixent approved in the EU as the first and only ...
Nov 6, 2024 · Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis. Approval based on phase 3 data showing significantly more children …
Press Room - Sanofi US News
Sep 11, 2024 · A Dupixent (dupilumab) confirmatory phase 3 study (LIBERTY-CUPID Study C) met the primary and key secondary endpoints for the investigational treatment of patients with …
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve ...
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial. Trial met …
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a …
1 day ago · Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight PR Newswire …
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a …
1 day ago · The Phase III BOREAS trial demonstrated that patients treated with DUPIXENT experienced a 30% reduction in moderate-to-severe exacerbations over 52 weeks, significant …
FDA Approves Dupixent® (dupilumab) as First Biologic Medicine …
Jun 7, 2022 · Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy through adulthood.
- Some results have been removed